Clinical trial / 2013
High-dose intravenous ascorbic acid was well tolerated in advanced cancer patients, but no objective antitumor responses were observed.
Five cohorts of three patients with advanced solid tumors received intravenous ascorbic acid at 1 g/min for 4 consecutive days per week for 4 weeks, starting at 30 g/m² with 20 g/m² dose escalations. Ascorbic acid was eliminated by first-order kinetics with a half-life of 2.0 ± 0.6 h and clearance of 21 ± 5 dL/h m². Cmax and AUC increased with dose up to 70 g/m² (reaching 49 mM and 220 h mM, respectively). All doses were well tolerated, but no patient demonstrated an objective antitumor response.
- Study type
- Phase I dose-escalation clinical trial
- Who was studied
- 15 patients with advanced solid tumors refractory to standard therapy (5 cohorts of 3 patients)
- What was measured
- Safety, tolerability, pharmacokinetics, and objective antitumor response
THE PAPER
Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer.
Stephenson CM, Levin RD, Spector T, Lis CG. Cancer Chemother Pharmacol, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.